🇺🇸 FDA
Pipeline program

SNDX-5613

SNDX-5613-0708

Phase 1 small_molecule active

Quick answer

SNDX-5613 for Acute Myeloid Leukemias is a Phase 1 program (small_molecule) at Syndax Pharmaceuticals Inc with 1 ClinicalTrials.gov record(s).

Program details

Company
Syndax Pharmaceuticals Inc
Indication
Acute Myeloid Leukemias
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials